<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">313</article-id><article-id pub-id-type="doi">10.17816/psaic313</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Clinical analysis</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинический разбор</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The course of the acute period of ischemic stroke after inravenous thrombolysis</article-title><trans-title-group xml:lang="ru"><trans-title>Течение острого периода инсульта после системного внутривенного тромболизиса</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Domashenko</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Домашенко</surname><given-names>M. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7682-6672</contrib-id><name-alternatives><name xml:lang="en"><surname>Maksimova</surname><given-names>Marina Yu.</given-names></name><name xml:lang="ru"><surname>Максимова</surname><given-names>Марина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Loskutnikov</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Лоскутников</surname><given-names>M. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4934-1423</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikonov</surname><given-names>Alexey A.</given-names></name><name xml:lang="ru"><surname>Никонов</surname><given-names>Алексей Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), neurologist, 2<sup>nd</sup> Neurological department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>к.м.н., врач-невролог 2-го неврологического отделения Института клинической и профилактической неврологии</p></bio><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bryukhov</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Брюхов</surname><given-names>Василий Валерьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Center of Neurology, Moscow</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-03-13" publication-format="electronic"><day>13</day><month>03</month><year>2011</year></pub-date><volume>5</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>52</fpage><lpage>57</lpage><history><date date-type="received" iso-8601-date="2017-02-03"><day>03</day><month>02</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2011, Domashenko M.A., Maksimova M.Y., Loskutnikov M.A., Nikonov A.A., Bryukhov V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2011, Domashenko M.A., Maksimova M.Y., Loskutnikov M.A., Nikonov A.A., Bryukhov V.V.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="en">Domashenko M.A., Maksimova M.Y., Loskutnikov M.A., Nikonov A.A., Bryukhov V.V.</copyright-holder><copyright-holder xml:lang="ru">Domashenko M.A., Maksimova M.Y., Loskutnikov M.A., Nikonov A.A., Bryukhov V.V.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/313">https://annaly-nevrologii.com/pathID/article/view/313</self-uri><abstract xml:lang="en"><p> </p><p>Intravenous (i.v.) thrombolytic therapy of acute ischemic stroke is highly effective in selected group of patients. The most common complications of systemic thrombolysis are intracerebral haematomas, allergic reactions and acute hypotension. The early reocclusion/rethrombosis of intracranial arteries also may influency the efficacy of thrombolysis. The clinical cases of allergic reactions, acute hypotension and early reocclusion in the first 24 hours after i.v. thrombolysis are described in the article. It is concluded that monitoring of neurological status and haemodynamic parameters during and 24 hours after i.v. thrombolysis are the important factors of good outcome.</p>  <p> </p> <p> </p></abstract><trans-abstract xml:lang="ru"><p>Внутривенная тромболитическая терапия (системный тромболизис) — высокоэффективный метод лечения определенной группы больных с ишемическим инсультом (ИИ). Применение тромболизиса связано с риском осложнений и потому имеет ряд ограничений, основные из которых — интрацеребральные гематомы, аллергические реакции, падение АД. Еще одно осложнение тромболитической терапии — ранняя реокклюзия (ретромбоз) интракраниальных артерий. Описаны клинические случаи развития аллергической реакции, падения АД и ранней реокклюзии в первые сутки после проведения системного тромболизиса. Подчеркивается, что важным условием благоприятного исхода при применении системного тромболизиса (помимо соблюдения протокола его проведения) является тщательный мониторинг за состоянием пациента с оценкой неврологического статуса и показателей системной гемодинамики, как во время тромболитической терапии, так и в течение первых суток после системного тромболизиса.</p></trans-abstract><kwd-group xml:lang="en"><kwd>thrombolysis</kwd><kwd>ischemic stroke</kwd><kwd>complications</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>тромболизис</kwd><kwd>ишемический инсульт</kwd><kwd>осложнения</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему. Анналы клинической и экспериментальной неврологии 2007; 1: 17–22.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Adams H. et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007; 38: 1655–1711.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ahmed N. et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITSISTR. Lancet Neurology 2010; 9: 866–874.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Alexandrov A.V., Grotta J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002, 59 (6): 862–867.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008. http://www.eso-stroke.org/recommendations</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lansberg M.G. et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007; 38: 2275–2278.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Wardlaw C., Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke. BMJ, 2003 (1); 326 (7383): 233–234.</mixed-citation></ref></ref-list></back></article>
